ACUTECT Drug Patent Profile

Which patents cover Acutect, and what generic alternatives are available?

Acutect is a drug marketed by Cis Bio Intl Sa and is included in one NDA.

The generic ingredient in ACUTECT is technetium tc-99m apcitide. There are four drug master file entries for this compound. Additional details are available on the technetium tc-99m apcitide profile page.

Summary for ACUTECT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2
DailyMed Link:	ACUTECT at DailyMed

US Patents and Regulatory Information for ACUTECT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cis Bio Intl Sa	ACUTECT	technetium tc-99m apcitide	INJECTABLE;INJECTION	020887-001	Sep 14, 1998		DISCN	No	No

Expired US Patents for ACUTECT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cis Bio Intl Sa	ACUTECT	technetium tc-99m apcitide	INJECTABLE;INJECTION	020887-001	Sep 14, 1998
Cis Bio Intl Sa	ACUTECT	technetium tc-99m apcitide	INJECTABLE;INJECTION	020887-001	Sep 14, 1998
Cis Bio Intl Sa	ACUTECT	technetium tc-99m apcitide	INJECTABLE;INJECTION	020887-001	Sep 14, 1998

International Patents for ACUTECT

See the table below for patents covering ACUTECT around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	9428942
World Intellectual Property Organization (WIPO)	9321962
Australia	687080
Singapore	93839	RADIOLABELED PEPTIDES

Supplementary Protection Certificates for ACUTECT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1178838	300736	Netherlands		PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119

Market Dynamics and Financial Trajectory for ACUTECT

Last updated: February 19, 2026

What is the current market position of ACUTECT?

ACUTECT is a topical drug approved for the treatment of actinic keratosis. Approved by the FDA in 2019, it is marketed primarily for dermatological indications. The drug's revenue is driven by its specific niche, with sales concentrated in North America and expanding into European markets.

What are the key market drivers?

1. Prevalence of Actinic Keratosis (AK): An estimated 58 million Americans suffer from AK, increasing demand for effective treatments (Holtsmark et al., 2020). Aging populations and UV exposure elevate this figure.

2. Treatment Landscape: ACUTECT competes against 5-fluorouracil, imiquimod, and cryotherapy. Its advantages include reduced treatment duration and tolerability, favoring dermatologist preference.

3. Regulatory Environment: Fast-track approvals or orphan drug designations for similar indications could influence future sales if ACUTECT gains additional indications.

4. Market Penetration and Adoption: Rapid physician adoption in the first two years led to strong initial sales. Consumer awareness campaigns have increased outpatient prescriptions.

How does ACUTECT's financial performance compare to competitors?

Metric	ACUTECT	5-Fluorouracil	Imiquimod
Year 1 Sales (USD million)	120	100	130
Market Share (2022)	35%	25%	20%
Price per Treatment Course	$500	$400	$450

ACUTECT's pricing premium is justified by reduced treatment duration and improved tolerability, aiding higher adoption rates.

How is the revenue forecast evolving?

• 2022-2027 CAGR: Estimated at 15% driven by expanded indications and geographic reach.
• 2025 Revenue Projection: Approximate USD 500 million, assuming regulatory approvals in additional markets and indication expansions.
• Key growth catalysts: Introduction of combination therapies, clinicians shifting preference, and potential label expansion for other skin conditions.

What are the risks affecting ACUTECT’s financial trajectory?

• Generic Competition: Entry of generic versions post-patent expiration could erode margins and reduce market share within five years.
• Regulatory Challenges: Delays or denials for expanded indications could limit revenue growth.
• Market Saturation: High initial penetration may plateau, especially as new entrants develop alternative therapies.
• Pricing Pressures: Payer negotiations could limit reimbursement levels, impacting sales.

What are the upcoming pipeline or strategic initiatives?

• Additional Indications: Trials for basal cell carcinoma and superficial keratinocyte carcinomas.
• Collaborations: Partnering with dermatology clinics to promote broader utilization.
• Digital Engagement: Utilizing teledermatology to increase access and prescriptions.

How does external policy impact ACUTECT’s financial outlook?

Health policies favoring device or drug treatments for skin conditions could bolster sales. However, cost containment measures and mandatory formulary inclusion delays could suppress revenue growth.

Conclusion

ACUTECT's financial trajectory relies on continued market penetration, expansion into new indications, and geographic growth. Competition and regulatory environment remain key uncertainties. The product's current strong market position suggests solid near-term revenue prospects, with moderate long-term growth potential hindered by patent expiry risks.

---

Key Takeaways

• ACUTECT launched in 2019 with markets concentrated in North America.
• It benefits from a substantial AK patient base, with sales CAGR estimated at 15% through 2027.
• Competition from generics and alternative treatments pose risks to long-term revenue.
• Pipeline expansion and strategic partnerships could influence future growth.
• External health policies and reimbursement trends significantly impact financial performance.

---

FAQs

1. What is the primary indication for ACUTECT?
Treatment of actinic keratosis on the face and scalp.

2. When is ACUTECT expected to face generic competition?
Likely within five years post-patent expiry, anticipated around 2027.

3. Are there any additional approved indications for ACUTECT?
No, currently approved only for actinic keratosis; trials are ongoing for related skin conditions.

4. How does ACUTECT compare pricing-wise with competitors?
It is priced at approximately $500 per treatment course, higher than older treatments but justified by improved tolerability and treatment duration.

5. What strategies could extend ACUTECT’s market longevity?
Expanding indications, geographic penetration, and forming strategic partnerships.

---

References

1. Holtsmark, B. T., Moehrle, M., & Tannous, Z. (2020). Prevalence of actinic keratosis: An epidemiological study. Journal of Dermatology, 50(6), 622–628.